Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients
- PMID: 18403218
- DOI: 10.1016/j.jdiacomp.2008.02.002
Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients
Abstract
In this retrospective real-world study, we aimed to evaluate whether switching from the pathogenetic treatment option alpha-lipoic acid to drugs for symptomatic treatment of neuropathic pain such as gabapentin would be associated with changes in efficacy, safety, and cost-effectiveness. A cohort of 443 diabetic patients with chronic painful neuropathy were treated with alpha-lipoic acid 600 mg qd orally for a mean period of 5 years. After stopping this treatment, 293 patients were switched to gabapentin (600-2400 mg/day), while 150 patients remained untreated because of no acute symptoms. In the untreated group, 110 (73%) patients developed neuropathic symptoms as soon as 2 weeks after the end of treatment with alpha-lipoic acid. In the group started on gabapentin, 131 (45%) patients had to stop taking the drug due to intolerable side effects. Among the patients treated with gabapentin 132 (45%) were responders on an average dose of 1200 mg/day, whereas 161 (55%) were nonresponders at gabapentin doses up to 2400 mg/day. These patients required an alternative treatment which consisted of pregabalin, carbamazepine, amitriptyline, tramadol, or morphine as monotherapy or in combination. The daily costs for alpha-lipoic acid were considerably lower than those for gabapentin or several frequently used drug combinations. The frequency of outpatient visits was 3.8 times per 3 months during the treatment period with alpha-lipoic acid, while it increased to 7.9 per 3 months after switching to gabapentin or the other pain medications. In conclusion, switching from long-term treatment with alpha-lipoic acid to central analgesic drugs such as gabapentin in painful diabetic neuropathy was associated with considerably higher rates of side effects, frequencies of outpatient visits, and daily costs of treatment. The pathogenic treatment option represents for the practicing diabetologist an effective, safe, and cost-effective treatment option for the majority of patients with diabetic polyneuropathy.
Similar articles
-
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.Clin Ther. 2006 Nov;28(11):1922-34. doi: 10.1016/j.clinthera.2006.11.017. Clin Ther. 2006. PMID: 17213013
-
Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.Clin Ther. 2010 Jul;32(7):1357-70. doi: 10.1016/j.clinthera.2010.07.014. Clin Ther. 2010. PMID: 20678683
-
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.J Med Econ. 2012;15(2):361-70. doi: 10.3111/13696998.2011.650773. Epub 2012 Jan 9. J Med Econ. 2012. PMID: 22181052
-
Diabetic neuropathy: new strategies for treatment.Diabetes Obes Metab. 2008 Feb;10(2):99-108. doi: 10.1111/j.1463-1326.2007.00741.x. Epub 2007 Jun 26. Diabetes Obes Metab. 2008. PMID: 17593238 Review.
-
Clinical inquiry: what medications are best for diabetic neuropathic pain?J Fam Pract. 2012 Nov;61(11):691-3. J Fam Pract. 2012. PMID: 23256101 Review.
Cited by
-
Diabetic neuropathic pain: Physiopathology and treatment.World J Diabetes. 2015 Apr 15;6(3):432-44. doi: 10.4239/wjd.v6.i3.432. World J Diabetes. 2015. PMID: 25897354 Free PMC article. Review.
-
Strategies and methods for the treatment of diabetic neuropathy using integrative Chinese and Western medicine.Chin J Integr Med. 2008 Dec;14(4):245-7. doi: 10.1007/s11655-008-0245-7. Epub 2008 Dec 12. Chin J Integr Med. 2008. PMID: 19082793 No abstract available.
-
Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway.J Neurosci. 2009 Jul 29;29(30):9500-9. doi: 10.1523/JNEUROSCI.5803-08.2009. J Neurosci. 2009. PMID: 19641113 Free PMC article.
-
Efficacy of different doses of atorvastatin treatment on serum levels of 8-hydroxy-guanin (8-OHdG) and cardiac function in patients with ischemic cardiomyopathy.Pak J Med Sci. 2015 Jan-Feb;31(1):37-42. doi: 10.12669/pjms.311.5840. Pak J Med Sci. 2015. PMID: 25878611 Free PMC article.
-
Expert opinion on screening, diagnosis and management of diabetic peripheral neuropathy: a multidisciplinary approach.Front Endocrinol (Lausanne). 2024 Jun 17;15:1380929. doi: 10.3389/fendo.2024.1380929. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38952393 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical